Literature DB >> 31437650

A retrospective analysis of the pathogens in the airways of patients with primary ciliary dyskinesia.

Lukas Roden1, Dennis Görlich2, Heymut Omran3, Georg Peters4, Jörg Große-Onnebrink5, Barbara C Kahl6.   

Abstract

INTRODUCTION: Primary ciliary dyskinesia (PCD) is a rare genetically heterogeneous disorder of motile cilia, which leads to recurrent and chronic airway infections. Detailed information about infection causing pathogens is scarce. With this study, we aimed to determine the prevalence and susceptibility of the most common respiratory pathogens in PCD patients retrospectively in a cross-sectional and the dynamics of the microbiological diversity in a longitudinal study.
METHODS: Microbiological and clinical data of 106 patients between 2010 and 2016 were analysed cross-sectionally and of 28 patients longitudinally. Dynamics in microbiological diversity were assessed by calculating the mean rate of alteration (MRA).
RESULTS: Haemophilus influenzae was the most common pathogen (n = 41; 38.7%) followed by Staphylococcus aureus (n = 36; 34%), Moraxella catarrhalis (n = 18; 17%) and Pseudomonas aeruginosa (n = 16; 15.1%). Nontuberculous mycobacteria were cultured from two patients (1.9%). H. influenzae was the most prevalent pathogen in children (n = 31; 45.6%), S. aureus in adults (n = 15; 39%). Two patients were infected by methicillin-resistant S. aureus. P. aeruginosa was mostly susceptible to standard antibiotics with highest rates of resistance against fosfomycin (63.6%; 7/11). The culture of P. aeruginosa correlated negatively with age adjusted FEV1% predicted (p = 0.04), while the MRA was positively associated with age (rho 0.411, p = 0.032). DISCUSSION: In PCD patients, the prevalence of pathogens differed in children and adults with H. influenzae and S. aureus being the most common pathogens in children, S. aureus and P. aeruginosa in adults, respectively. Unexpectedly, the MRA increased by age.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Lung function; Microbiological diversity; P. aeruginosa; Prevalence; Primary ciliary dyskinesia; S. aureus; Susceptibility

Mesh:

Year:  2019        PMID: 31437650     DOI: 10.1016/j.rmed.2019.08.009

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  4 in total

Review 1.  Lower airway clinical outcome measures for use in primary ciliary dyskinesia research: a scoping review.

Authors:  Florian Gahleitner; James Thompson; Claire L Jackson; Jana F Hueppe; Laura Behan; Eleonora Dehlink; Myrofora Goutaki; Florian Halbeisen; Ana Paula L Queiroz; Guillaume Thouvenin; Claudia E Kuehni; Philipp Latzin; Jane S Lucas; Bruna Rubbo
Journal:  ERJ Open Res       Date:  2021-11-29

2.  A retrospective review of Achromobacter species and antibiotic treatments in patients with primary ciliary dyskinesia.

Authors:  Mathias G Holgersen; June K Marthin; Helle K Johansen; Kim G Nielsen
Journal:  Chron Respir Dis       Date:  2021 Jan-Dec       Impact factor: 2.444

3.  Primary ciliary dyskinesia in Volendam: Diagnostic and phenotypic features in patients with a CCDC114 mutation.

Authors:  Renate Kos; Joël Israëls; Christine D L van Gogh; Josje Altenburg; Sandra Diepenhorst; Tamara Paff; Elles M J Boon; Dimitra Micha; Gerard Pals; Anne H Neerincx; Anke H Maitland-van der Zee; Eric G Haarman
Journal:  Am J Med Genet C Semin Med Genet       Date:  2022-03-27       Impact factor: 3.359

4.  Association of Diverse Staphylococcus aureus Populations with Pseudomonas aeruginosa Coinfection and Inflammation in Cystic Fibrosis Airway Infection.

Authors:  Marie K Wieneke; Felix Dach; Claudia Neumann; Dennis Görlich; Lena Kaese; Theo Thißen; Angelika Dübbers; Christina Kessler; Jörg Große-Onnebrink; Peter Küster; Holger Schültingkemper; Bianca Schwartbeck; Johannes Roth; Jerzy-Roch Nofer; Janina Treffon; Julia Posdorfer; Josefine Marie Boecken; Mariele Strake; Miriam Abdo; Sophia Westhues; Barbara C Kahl
Journal:  mSphere       Date:  2021-06-23       Impact factor: 4.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.